Amgen's (AMGN) “Buy” Rating Reaffirmed at Mizuho – BharataPress

Amgen's (AMGN) “Buy” Rating Reaffirmed at Mizuho
BharataPress
After speaking with two physicians who treat between 50-100 patients per month for cellulite to discuss the market opportunity for ENDP's CCH, we are increasingly more positive on the market opportunity for this product, if approved. … The company's

Read more:

About the Author AdelinaDuh

Leave a Comment: